Clinical trials: Living Donor of Kidney
Liver Transplant; Complications, AKI - Acute Kidney Injury
The Efficacy of Intravenous Amino Acids in Reducing the Occurrence of AKI After Live Donor Liver Transplant
This prospective, open-label, randomized controlled trial aims to evaluate the efficacy of intravenous amino acid infusion in reducing AKI after LDLT.
- Trial name
- NCT07132697
- Testing
- L-Amino acid mixture, Standard of care
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Kidney Transplant; Complications, Renal Failure Chronic
The Outcomes of Living Donor Robotic Assisted Kidney Transplantation
The technology for robot-assisted kidney transplantation (RAKT) has become increasingly advanced, with numerous studies demonstrating comparable outcomes between RAKT surgery and open surgery.
- Trial name
- RAKT (NCT06577805)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- West China Hospital
End-Stage Renal Disease, Living Donors
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
The purpose of this study is to observe in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with the…
- Trial name
- NCT01046955
- Testing
- Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
End Stage Renal Disease
Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant
Because of the deceased donor organ shortage, more kidney patients are considering whether to receive kidneys from family and friends, a process called living donor kidney transplantation (LDKT).
- Trial name
- NCT02181114
- Testing
- Expert System Coaching
- Where
- 2 sites in United States
- Volunteers
- 815 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Failure
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion
An open-label study to assess the safety, efficacy, and tolerance of FCRx cell therapy in adult recipients within 12 months after kidney transplantation from a living donor.
- Trial name
- NCT00497926
- Testing
- Enriched Hematopoietic Stem Cell Infusion
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Talaris Therapeutics Inc.
End Stage Renal Disease
Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation
The purpose of this study is to offer Panel Reactive Antibodies [PRA] reduction treatment to high responder renal transplant patients who otherwise may never be compatible with a potential organ donor.
- Trial name
- NCT00784979
- Testing
- CMVIG
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Tampa General Hospital